Colorectal Cancer :: KRAS mutation in colorectal cancer patients treated with Cetuximab
Mutations in the KRAS oncogene could predict a lack of response to the drug cetuximab in patients with colorectal tumors. For those with the mutations, the drug is likely to be inefficient and possibly harmful, according to researchers at France?s Institut National de la Sante et de la Recherche Medicale (INSERM).